期刊
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
卷 18, 期 12, 页码 769-772出版社
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clml.2018.10.007
关键词
Acute myeloid leukemia; Beta-hydroxyglutarate; Enasidenib; Isocitrate dehydrogenase; Ivosidenib
Mutations in isocitrate dehydrogenase isoform (IDH) 1 and 2 occur in approximately 25% of patients with acute myeloid leukemia (AML). These mutations lead to a block in myeloid differentiation and ultimately, to the development of AML. Inhibitors of mutant IDH1 and 2 have recently been approved by the US Food and Drug Administration and their use has led to clinical responses with prolonged duration of response. IDH inhibitors in combination with standard-of-care therapy and other small molecular inhibitors are now being used. (C) 2018 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据